AGL 39.50 Increased By ▲ 1.48 (3.89%)
AIRLINK 208.03 Increased By ▲ 10.67 (5.41%)
BOP 9.60 Increased By ▲ 0.06 (0.63%)
CNERGY 6.01 Increased By ▲ 0.10 (1.69%)
DCL 9.10 Increased By ▲ 0.28 (3.17%)
DFML 36.05 Increased By ▲ 0.31 (0.87%)
DGKC 99.49 Increased By ▲ 2.63 (2.72%)
FCCL 35.45 Increased By ▲ 0.20 (0.57%)
FFBL 88.94 Increased By ▲ 6.64 (8.07%)
FFL 13.40 Increased By ▲ 0.23 (1.75%)
HUBC 128.08 Increased By ▲ 0.53 (0.42%)
HUMNL 13.75 Increased By ▲ 0.25 (1.85%)
KEL 5.39 Increased By ▲ 0.07 (1.32%)
KOSM 7.10 Increased By ▲ 0.10 (1.43%)
MLCF 45.25 Increased By ▲ 0.55 (1.23%)
NBP 61.79 Increased By ▲ 0.37 (0.6%)
OGDC 218.00 Increased By ▲ 3.33 (1.55%)
PAEL 39.80 Increased By ▲ 1.01 (2.6%)
PIBTL 8.37 Increased By ▲ 0.12 (1.45%)
PPL 195.50 Increased By ▲ 2.42 (1.25%)
PRL 39.15 Increased By ▲ 0.49 (1.27%)
PTC 27.01 Increased By ▲ 1.21 (4.69%)
SEARL 105.74 Increased By ▲ 2.14 (2.07%)
TELE 8.36 Increased By ▲ 0.06 (0.72%)
TOMCL 35.50 Increased By ▲ 0.50 (1.43%)
TPLP 13.55 Increased By ▲ 0.25 (1.88%)
TREET 22.65 Increased By ▲ 0.49 (2.21%)
TRG 59.65 Increased By ▲ 4.06 (7.3%)
UNITY 33.50 Increased By ▲ 0.53 (1.61%)
WTL 1.71 Increased By ▲ 0.11 (6.88%)
BR100 11,889 Increased By 162.9 (1.39%)
BR30 36,977 Increased By 600.2 (1.65%)
KSE100 111,245 Increased By 1732 (1.58%)
KSE30 35,056 Increased By 542.6 (1.57%)

AstraZeneca on Friday beat first-quarter sales and profit expectations and stood by its forecasts for 2022 as newer therapies for kidney disease and rare conditions offset an expected decline in COVID-19 vaccine sales.

It expects sales of its antibody-based COVID-19 treatment, Evusheld, to grow this year, but that will be more than outweighed by a decline in sales of its vaccine developed with Oxford University amid growing competition, concerns about its shelf life and vaccine hesitancy.

The vaccine recorded $1.15 billion in sales in the quarter, the majority of which came from initial contracts, while the antibody treatment brought in $469 million.

The two-dose shot was AstraZeneca’s second best-selling product in 2021 with sales of $3.9 billion.

AstraZeneca’s total revenue jumped 60% to $11.39 billion for the three months ended March 31 on a constant-currency basis.

Core earnings of $1.89 per share were helped by strong sales of products such as Farxiga for diabetes and kidney and the vaccine.

Analysts on average were expecting profit of $1.70 per share on revenue of $10.85 billion, Refinitiv IBES data showed.

However, sales of its top three oncology drugs - Tagrisso, Imfinzi and Lynparza - missed consensus expectations.

Even though COVID-19 levels are beginning to wane, access to cancer diagnoses and treatment has still not rebounded to pre-pandemic levels.

Comments

Comments are closed.